Dennis Kennedy's questions to Scholar Rock Holding Corp (SRRK) leadership • Q1 2025
Question
Dennis Kennedy asked for expectations for the tirzepatide monotherapy arm in the EMBRAZE study, specifically regarding the extent of lean mass loss by week 24 and whether the 8-week follow-up is sufficient to observe weight regain.
Answer
President of R&D Akshay Vaishnaw explained that they expect the tirzepatide arm to show lean mass loss consistent with historical data, around 25-30% of total weight loss at 24 weeks. He acknowledged the 8-week follow-up is short but stated the trajectory of weight change between the study arms during that period will still provide important insights.